Russell Investments Group, Ltd. Tricida, Inc. Transaction History

Russell Investments Group, Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 04, 2022	BUY	$8.51 - $13.6 $50,285 - $80,362	5,909 Added 43.48%	19,500 $203,000
Q2 2022 Jul 29, 2022	SELL	$7.31 - $11.85 $24,108 - $39,081	-3,298 Reduced 19.53%	13,591 $130,000
Q1 2022 May 05, 2022	SELL	$7.35 - $10.63 $88,839 - $128,484	-12,087 Reduced 41.71%	16,889 $138,000
Q4 2021 Jan 21, 2022	SELL	$4.19 - $9.56 $92,582 - $211,237	-22,096 Reduced 43.26%	28,976 $276,000
Q3 2021 Nov 08, 2021	SELL	$3.56 - $4.64 $35,375 - $46,107	-9,937 Reduced 16.29%	51,072 $236,000
Q2 2021 Aug 04, 2021	SELL	$3.95 - $5.41 $23,301 - $31,913	-5,899 Reduced 8.82%	61,009 $262,000
Q1 2021 May 10, 2021	SELL	$4.52 - $7.8 $52,273 - $90,207	-11,565 Reduced 14.74%	66,908 $352,000
Q4 2020 Feb 08, 2021	BUY	$4.37 - $9.46 $125,130 - $270,877	28,634 Added 57.45%	78,473 $551,000
Q3 2020 Nov 09, 2020	BUY	$8.56 - $26.93 $144,826 - $455,628	16,919 Added 51.39%	49,839 $450,000
Q2 2020 Aug 05, 2020	BUY	$21.21 - $31.55 $698,233 - $1.04 Million	32,920 New	32,920 $902,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.